All In Biotech

Drug Trial Radar · NCT02597933

A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis

A Double Blind, Randomised, Placebo-controlled Trial Evaluating Efficacy and Safety of Oral Nintedanib Treatment for at Least 52 Weeks in Patients With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)

Last checked: Nov 20, 2026Latest source record: Dec 13, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 580 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

580

Actual

Start

Nov 12, 2015

Primary completion

Oct 31, 2018

Study completion Nov 28, 2018

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Nov 5, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Systemic Sclerosis (SSc) is a devastating disease of unknown etiology. Patients suffer from multiple organ fibrosis whereas lung fibrosis (interstitial lung disease, ILD) is one of the main driver for mortality. There is preclinical evidence for efficacy of nintedanib in SSc and associated ILD (SSc-ILD) and the anti-fibrotic efficacy of nintedanib was proven in idiopathic pulmonary fibrosis patients, who are presenting a similar pattern regarding lung fibrosis. Hence it is the purpose of the trial to confirm the efficacy and safety of nintedanib 150 mg bid in treating patients with SSc-ILD, compared with placebo. The trial will be conducted as a double blind, randomised, placebo-controlled trial with primary efficacy evaluation at week 52 and placebo-controlled treatment until last patient out (up to a maximum of 100 weeks). Respiratory function is globally accepted for assessment of treatment effects in patients with lung fibrosis. The chosen endpoint (Forced Vital Capacity (FVC) decline) is easy to obtain and is part of the usual examinations done in patients with SSc-ILD.

Conditions

  • Scleroderma, Systemic

Interventions

  • NintedanibDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 WeeksTime frame: up to week (wk) 52 after the start of administration

Locations

195 sites in 32 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of California Los Angeles

    Los Angeles, California

  • University of California Davis

    Sacramento, California

  • University of California San Francisco

    San Francisco, California

  • Stanford University Medical Center

    Stanford, California

  • University of Colorado Denver

    Aurora, Colorado

  • Yale University School of Medicine

    New Haven, Connecticut

  • Georgetown University

    Washington D.C., District of Columbia

  • University of Florida College of Medicine

    Jacksonville, Florida

  • University of Miami

    Miami, Florida

  • The Emory Clinic

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • University of Iowa

    Iowa City, Iowa

  • University of Kansas Medical Center

    Kansas City, Kansas

  • University of Louisville

    Louisville, Kentucky

  • Tulane University Hospital and Clinic

    New Orleans, Louisiana

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Boston Medical Center

    Boston, Massachusetts

  • University of Michigan Health System

    Ann Arbor, Michigan

  • University of Minnesota Masonic Cancer Center

    Minneapolis, Minnesota

  • Mayo Clinic-Rochester

    Rochester, Minnesota

  • The Lung Research Center, LLC

    Chesterfield, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • Hospital for Special Surgery

    New York, New York

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Columbia University Medical Center-New York Presbyterian Hospital

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • University of Cincinnati Health

    Cincinnati, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • University of Toledo

    Toledo, Ohio

  • Penn State Milton S. Hershey Medical Center

    Hershey, Pennsylvania

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • Temple University Hospital

    Philadelphia, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • University of South Carolina

    Columbia, South Carolina

  • Vanderbilt Pulmonary Clinic

    Nashville, Tennessee

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • The University Of Texas at Houston

    Houston, Texas

  • University of Utah Health Sciences Center

    Salt Lake City, Utah

Showing 40 of 195 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.